Poolbeg Pharma, a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, has announced that it has signed a strategic collaboration agreement with a Nasdaq-listed biopharma company for the development of an optimised oral drug to treat a metabolic condition.
Under the agreement, the company will receive funding to work with its new partner to produce a prototype drug utilising Poolbeg’s licensed oral delivery technology.
Poolbeg has an exclusive licence to patented oral delivery technologies for all metabolic conditions and is utilising the same technology for its Oral GLP-1 agonist programme.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
